- Home
- DFH vs DYN Comparison
DFH vs DYN Comparison
Compare DFH & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFH
- DYN
- Stock Information
- Founded
- DFH 2008
- DYN 1984
- Country
- DFH United States
- DYN United States
- Employees
- DFH N/A
- DYN N/A
- Industry
- DFH Homebuilding
- DYN Medicinal Chemicals and Botanical Products
- Sector
- DFH Consumer Discretionary
- DYN Health Care
- Exchange
- DFH Nasdaq
- DYN Nasdaq
- Market Cap
- DFH 2.2B
- DYN 1.9B
- IPO Year
- DFH 2021
- DYN 2020
- Fundamental
- Price
- DFH $19.06
- DYN $21.33
- Analyst Decision
- DFH Hold
- DYN Strong Buy
- Analyst Count
- DFH 1
- DYN 15
- Target Price
- DFH $26.00
- DYN $36.53
- AVG Volume (30 Days)
- DFH 372.2K
- DYN 2.7M
- Earning Date
- DFH 10-30-2025
- DYN 11-05-2025
- Dividend Yield
- DFH N/A
- DYN N/A
- EPS Growth
- DFH N/A
- DYN N/A
- EPS
- DFH 2.84
- DYN N/A
- Revenue
- DFH $4,671,814,000.00
- DYN N/A
- Revenue This Year
- DFH N/A
- DYN N/A
- Revenue Next Year
- DFH $1.86
- DYN N/A
- P/E Ratio
- DFH $6.64
- DYN N/A
- Revenue Growth
- DFH 15.98
- DYN N/A
- 52 Week Low
- DFH $17.61
- DYN $6.36
- 52 Week High
- DFH $34.43
- DYN $31.32
- Technical
- Relative Strength Index (RSI)
- DFH 44.68
- DYN 58.33
- Support Level
- DFH $17.61
- DYN $19.67
- Resistance Level
- DFH $19.68
- DYN $22.27
- Average True Range (ATR)
- DFH 0.76
- DYN 1.67
- MACD
- DFH 0.26
- DYN -0.06
- Stochastic Oscillator
- DFH 77.14
- DYN 80.17
About DFH Dream Finders Homes Inc.
Dream Finders Homes Inc is engaged in the home building business. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the majority of its revenue from the Midwest segment.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.